GlassScriptPhysician profile
Emmanuel Ofori
NPI 1760881304
$4,308.49
in general payments reported to CMS, 2019-2025
26 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $163 · 2021: $740 · 2022: $647 · 2023: $541 · 2024: $1,023 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.53 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,074.98 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $637.20 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $614.15 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $520.05 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Olympus America INC. | $197.05 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.68 | 2021-2025 | Xifaxan |
| Qol Medical, LLC | $157.77 | 2021-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $141.29 | 2021-2024 | |
| Cook Medical LLC | $133.70 | 2022 | |
| Ambu INC. | $94.87 | 2020 | |
| Daiichi Sankyo INC. | $85.14 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $79.39 | 2021-2024 | Linzess |
| Celgene Corporation | $49.28 | 2022 | |
| Boston Scientific Corporation | $42.93 | 2021-2023 | Resolution Clip |
| Genzyme Corporation | $37.32 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $37.24 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $37.19 | 2019 | |
| Nestle Healthcare Nutrition INC. | $34.90 | 2023 | |
| Lilly USA, LLC | $34.62 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $30.67 | 2025 | Rezdiffra |
| Apollo Endosurgery US INC | $20.97 | 2023 | Overstitch Endoscopic Suturing System |
| Ipsen Biopharmaceuticals, INC | $17.40 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $16.49 | 2020 | |
| Ardelyx, INC. | $13.69 | 2025 | Ibsrela |
| Evoke Pharma, INC. | $11.87 | 2021 | |
| Organon LLC | $4.65 | 2025 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Ofori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.